Pathogenic Lysosomal Depletion in Parkinson's Disease
Benjamin Dehay(Centre National de la Recherche Scientifique), Miquel Vila(Institució Catalana de Recerca i Estudis Avançats)
Cited by 802
Related Papers
Targeting α-synuclein for treatment of Parkinson's disease: mechanistic and therapeutic considerations
|The Lancet Neurology|2015|508
D-β-Hydroxybutyrate rescues mitochondrial respiration and mitigates features of Parkinson disease
|Journal of Clinical Investigation|2003|412
D-β-Hydroxybutyrate rescues mitochondrial respiration and mitigates features of Parkinson disease
|Journal of Clinical Investigation|2003|402
Bax ablation prevents dopaminergic neurodegeneration in the 1-methyl- 4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease
|Proceedings of the National Academy of Sciences|2001|372
Complex I deficiency primes Bax-dependent neuronal apoptosis through mitochondrial oxidative damage
|Proceedings of the National Academy of Sciences|2005|310